Efficacy & Safety of Amlitelimab (An Anti-OX40 Ligand Antibody) in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2b Trial (STREAM-AD)
Time: 9:00 am
day: Conference Day Two
Details:
- Amlitelimab is a fully human, nondepleting anti-OX40 Ligand (OX40L) monoclonal antibody that blocks OX40L-OX40 interactions upstream of T-cell expansion and inflammatory cytokine production
- STREAM-AD (NCT05131477), a randomized, double-blind, placebo-controlled Phase 2b trial, included a 24-wk treatment period (Part 1), a 28-wk maintenance/withdrawal period (Part 2), and a 16-wk safety follow-up
- All four doses of amlitelimab demonstrated statistically significant improvements in percent change in EASI from baseline to Wk16 vs placebo. Clinically meaningful improvements in key secondary endpoints were observed at Wk16, with continued improvements through Wk24. In Part 2, maintenance of EASI-75 and/or IGA 0/1 response at Wk52 was observed in the majority of clinical responders withdrawn from amlitelimab demonstrating a durable off-drug response
